Sign In
Buy BIO
$301.90
-2.46 (-0.81%)
At Close: Jul 20, 2026
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
07:00am, Thursday, 23'rd May 2024
MINNEAPOLIS , May 23, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink Partners He
Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention
07:00am, Wednesday, 22'nd May 2024
Late clinical-stage company to provide update on Phase 3 treatment for celiac disease Late clinical-stage company to provide update on Phase 3 treatment for celiac disease
MINNEAPOLIS, May 22, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medici
Reviva to Participate in the BIO International Convention
08:00am, Tuesday, 21'st May 2024
CUPERTINO, Calif., May 21, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies t
BIO-key Expects to File Audited 2023 Results on Form 10-K and Report Q1 2024 Results and Host an Investor Call Next Week
04:55pm, Thursday, 16'th May 2024
HOLMDEL, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- BIO-key ® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Down
01:20pm, Wednesday, 08'th May 2024
Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Bio-Rad Laboratories, Inc. (BIO) Q1 2024 Earnings Call Transcript
11:16pm, Tuesday, 07'th May 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2024 Earnings Conference Call May 7, 2024 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer An
Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
06:31pm, Tuesday, 07'th May 2024
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.29 per share, beating the Zacks Consensus Estimate of $2.04 per share. This compares to earnings of $3.34 per share a year ago.
Bio-Rad Laboratories reiterates 2024 revenue growth outlook; shares slip
06:11pm, Tuesday, 07'th May 2024
Diagnostics firm Bio Rad Laboratories reiterated its 2024 sales growth forecast on Tuesday, weighed by persistently weak spending by biotech companies and sluggish demand in China.
Bio-Rad Reports First-Quarter 2024 Financial Results
04:15pm, Tuesday, 07'th May 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for t
Bio-Rad's Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference
09:00am, Wednesday, 01'st May 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operatin
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 30'th Apr 2024
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad Announces Life Science Group Management Changes
08:30am, Friday, 26'th Apr 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James
New Strong Sell Stocks for April 19th
05:26am, Friday, 19'th Apr 2024
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
11:06am, Thursday, 18'th Apr 2024
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
